Fig 1.
Model structure for drug-susceptible (DS)- and multidrug-resistant (MDR)-TB.
Table 1.
Parameter table.
Table 2.
Programmatic scenarios used in the model projections along with the evaluation of short-course MDR-TB regimens.
Fig 2.
Model projection of estimated TB incidence per 100,000 population, with credible intervals.
The black line shows the model results of estimated TB incidence, and the dots represent WHO data for estimated TB incidence.
Fig 3.
Model projection of estimated MDR-TB percentage among new TB cases.
The black line shows the model results of percentage of MDR-TB cases, and the dots represent WHO data for the estimated proportion of MDR-TB among new tuberculosis infections.
Fig 4.
Model projection of estimated numbers of MDR-TB cases.
The black line shows the model validation results of numbers of MDR-TB cases, and the dots represent WHO data for the numbers of estimated MDR-TB cases.
Fig 5.
Multi-way analysis focusing on three factors (eligibility, DST and treatment initiation) influencing the impacts from the short-course regimens (Table 2).
The outcomes in term overall MDR-TB cases (A-C) and MDR-TB percentage among new cases (D-F) from 81 combinations were simulated and compared to the baseline (using the standard regimen). Fig 3 categorized the outcomes by eligibility (A & D), DST (B & E), and treatment initiation (C & F)., shown in boxplots.